We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Zanidatamab Demonstrates Durable Antitumor Activity in HER2-Overexpressing Gastric Cancers.
- Authors
King, William
- Abstract
The article informs that HER2-targeted bispecific investigational antibody zanidatamab, either as monotherapy or in combination with chemotherapy, has shown antitumor activity in phase 1 clinical trial of patients with HER2-expressing biliary tract cancer or gastroesophageal adenocarcinoma. Topics include median progression-free survival rate; overall disease control rate; and approval of trastuzumab in combination with chemotherapy for HER2-overexpressing metastatic gastric. adenocarcinoma.
- Subjects
STOMACH cancer; BILIARY tract cancer
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 4, p20
- ISSN
2164-4403
- Publication type
Article